DNAnexus Expands Executive Team With Chief Technology Officer

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--DNAnexus, the leader in cloud-based genome informatics and data management, today announced that Mr. Balaji Venkateswaran has been named Chief Technology Officer of the growing bioinformatics company.

"I'm excited to be part of such a dynamic company which has been built on the security principles required to allow customers to conduct their DNA-based research on a global scale."

Venkateswaran brings more than twenty years of experience building highly-scalable global software products, many with a focus on security. Most recently he was Co-Founder and Vice President of Engineering at Layer8 Security, where he conceived and built an innovative cloud security platform. Prior to Layer8, he held various management and executive positions at Symantec, GuardianEdge Technologies (acquired by Symantec), Elemental Cyber Security, and Evolve Software (now part of Oracle). Venkateswaran has an MS in Computer Engineering from the University of South Carolina.

"Balaji has an impressive background of leading and growing teams that build world-class technology," said Richard Daly, CEO of DNAnexus. "His experience in security will benefit our customers as we continue to grow the global network that helps them securely and compliantly analyze, manage and share genomic data in the cloud."

"The intersection of genomic medicine and the cloud is disrupting medical discovery as we know it," added Mr. Venkateswaran. "I'm excited to be part of such a dynamic company which has been built on the security principles required to allow customers to conduct their DNA-based research on a global scale."

About DNAnexus

DNAnexus combines expertise in cloud computing and bioinformatics to create the global network for genomic medicine. DNAnexus provides security, scalability and collaboration for enterprises and organizations that are pursuing genomic-based approaches to health in order to accelerate medical discovery. DNAnexus is supporting customers around the world that are tackling some of the most challenging and exciting opportunities in human health. For more information, please visit: https://dnanexus.com and follow us at @DNAnexus.

Contacts

Element Public Relations
Tim Smith, 415-350-3019
[email protected]

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.